Sign in
TerminatedPhase 2

Lenalidomide and Rituximab in Treating Patients With Non-Hodgkin Lymphoma

Key facts

Who runs it
University of California, Davis
Where
Sacramento, United StatesSee the site
Trial code
Status
Terminated
Phase
Phase 2
People taking part
30 people enrolled
Started
25 Aug 2008
Ended
15 Apr 2024
Type of study
Interventional
Treatments tested
  • Rituximab
  • Lenalidomide
Record updated
24 April 2025
Why it stopped
Poor accrual

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (33)Hide the full registry criteria

Other criteria

  • DISEASE CHARACTERISTICS:
  • Histologically* confirmed non-Hodgkin lymphoma, including one of the following subtypes:; Grade 1, 2, or 3a (> 15 centroblasts per high-power field with centrocytes present) follicular lymphoma according to WHO criteria; Small lymphocytic lymphoma
  • NOTE: *Bone marrow biopsies as the sole means of diagnosis are not acceptable, but they may be submitted in conjunction with nodal biopsies or extra-nodal biopsies; fine-needle aspirates are not acceptable for diagnosis
  • At least one measurable lesion according to RECIST criteria; Measurable lymphadenopathy to follow with serial exam and/or imaging
  • Relapsed or refractory disease; Must have evidence of disease progression during or after last treatment; If previously treated with rituximab, must have disease progression within 6 months of last therapy OR if there was a prior response to rituximab, rituximab must not have been given within the past 6 months
  • No evidence of CNS metastases; PATIENT CHARACTERISTICS:
  • ECOG performance status 0-2
  • Life expectancy > 3 months
  • Absolute neutrophil count ≥ 1,000/mm³
  • Platelet count ≥ 75,000/mm³
  • Serum creatinine ≤ 2.0 mg/dL
  • Total bilirubin ≤ 2.0 mg/dL
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective double method contraception for ≥ 28 days before, during, and for ≥ 28 days after completion of study therapy
  • HIV negative
  • Able to swallow lenalidomide
  • Able to take aspirin (81 or 325 mg) daily or low molecular weight heparin as prophylactic anticoagulation
  • No neuropathy ≥ grade 2
  • No known active hepatitis A, B, or C
  • No other malignancies within the past 5 years except treated basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix or breast
  • No serious medical condition, laboratory abnormality, or psychiatric illness that would preclude the patient from signing the informed consent form
  • No condition, including the presence of laboratory abnormalities, that would preclude study participation or confound the ability to interpret study data
  • No known hypersensitivity to thalidomide or rituximab
  • No development of erythema nodosum, if characterized by a desquamating rash while taking thalidomide or similar drugs; PRIOR CONCURRENT THERAPY:
  • See Disease Characteristics
  • At least 4 weeks since prior anticancer therapy, including radiotherapy, hormonal therapy, or surgery
  • More than 28 days since prior experimental drug or therapy
  • No prior lenalidomide
  • No other concurrent anticancer agents or treatments, including radiotherapy or thalidomide
  • No other concurrent investigational agents
  • No concurrent sargramostim (GM-CSF)
  • No other concurrent antilymphoma therapy, including steroids (except for the treatment of hypersensitivity reactions)

Where in United States

  • University of California Davis Cancer CenterSacramento, United States

About the trial

What the trial wants to find out

RATIONALE: Biological therapies, such as lenalidomide, may stimulate the immune system in different ways and stop cancer cells from growing. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Giving lenalidomide together with rituximab may kill more cancer cells.

Read full original descriptionShow less

PURPOSE: This phase II trial is studying how well giving lenalidomide together with rituximab works in treating patients with follicular or small lymphocytic non-Hodgkin lymphoma that has relapsed or not responded to treatment.

The group in the trial

  • Lenalidomide and RituximabTreatment being tested

    Rituximab 375 mg/m2/wk x 4 weeks, to begin Cycle 1, Day 15. Lenalidomide 20 mg daily, days 1-21 of a 28 day cycle, to begin Day 1 of cycle 1 and continue until disease progression.

    Treatment: Rituximab and Lenalidomide

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase II Trial of the Combination of Lenalidomide and Rituximab in Patients With Relapsed/Refractory Follicular NHL (RV 0163)
Record updated
24 April 2025